NAMS vs VNDA: fair value comparison
NewAmsterdam Pharma Company N.V. and Vanda Pharmaceuticals Inc. · Updated 2026-10-19
NAMS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. VNDA is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, NAMS currently ranks higher by quality score.
| NAMS | VNDA | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $19.83 | $4.03 |
| 12-month range | $19.83–$41.45 | $4.03–$9.56 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #137 of 301 Healthcare | #139 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: NAMS fair value analysis · VNDA fair value analysis